J Hepatol. 2018;69:461-511. EASL recommendations on treatment of Hepatitis C 2018. PubMed 

Drug Metab Dispos. 2017;45:86-108. What can be learned from recent new drug applications? A systematic review of drug interaction data for drugs approved by the US FDA in 2015. Yu J, Zhou Z, Owens KH, Ritchie TK, Ragueneau-Majlessi I. PubMed

Liver Int. 2017; In press. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Aubé C, Oberti F, Lonjon J, Pageaux G, Seror O, N'Kontchou G, Rode A, Radenne S, Cassinotto C, Vergniol J, Bricault I, Leroy V, Ronot M, Castera L, Michalak S, Esvan M, Vilgrain V; CHIC group. PubMed

J Hepatol. 2017;66:153-194 LIVER DISEASES. EASL treatment of Hepatitis C 2016. Coordinator: Jean-Michel Pawlotsky; Panel members: Alessio Aghemo, David Back, Geoffrey Dusheiko, Xavier Forns, Francesco Negro, Massimo Puoti, Christoph Sarrazin. PubMed

J Hepatol. 2016; 65:396-398.  LIVER DISEASES AND IMAGING. EASL Clinical practice. Guidelines on the management of benign liver tumours. Colombo M, Forner A, Ijzermans J, Paradis V, Reeves H, Vilgrain V, Zucman-Rossi. J. PubMed

Eur Radiol. 2016;26:921-31. IMAGING ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Neri E, Bali MA, Ba-Ssalamah A, Boraschi P, Brancatelli G, Alves FC, Grazioli L, Helmberger T, Lee JM, Manfredi R, Martì-Bonmatì L, Matos C, Merkle EM, Op De Beeck B, Schima W, Skehan S, Vilgrain V, Zech C, Bartolozzi. PubMed

J Hepatol. 2015;63:199-236. EASL Recommendations on treatment of hepatitis C 2015. EASL. Pawlotsky JM, Aghemo A, Back D, Dusheiko G, Forns X, Puoti M, Sarrazin C. Drug transporters on pages 7-10. PubMed